Characterization of treatment and outcomes in a population-based cohort of patients with chronic lymphocytic leukemia referred for cytogenetic testing in British Columbia, Canada.

摘要: This study evaluates outcomes in chronic lymphocytic leukemia (CLL) based on first-line therapy a large consecutive population-based cohort of 669 patients with fluorescence in-situ hybridization (FISH) data British Columbia, Canada during the period when chemoimmunotherapy was standard treatment. When analyzed as time-dependent variable, who required treatment (n=336) had 4.7 times higher hazard death than did not (95% confidence interval 2.8-7.9, P<0.001). The majority received fludarabine-rituximab (FR) front-line. On multivariate Cox regression analysis, fludarabine-based predicted longer time-to-next-treatment (TTNT) (HR 0.53, 95% 0.33-0.87, P=0.012) but no difference overall survival (OS) compared to alkylator-based therapy. Deletion 17p an independent predictor worse TTNT and OS. most common second-line treatments were cyclophosphamide-vincristine-prednisone-rituximab FR. There OS between retreated same regimen (n=33) versus different (n=113). In conclusion, front-line fludarabine leads time until need for next therapy; however, or alkylator produces provides historical baseline comparison novel agents CLL population-level.